FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy

BACKGROUND: The role and sequencing of combination immuno-oncology (IO) therapy following progression on or after first-line IO therapy has not been well-established. The Fast Real-time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) program is an open-label, phase 2 platform trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Choueiri, Toni K, Kluger, Harriet, George, Saby, Tykodi, Scott S, Kuzel, Timothy M, Perets, Ruth, Nair, Suresh, Procopio, Giuseppe, Carducci, Michael A, Castonguay, Vincent, Folefac, Edmund, Lee, Chung-Han, Hotte, Sebastien J., Miller,, Wilson H, Saggi, Shruti Shally, Lee, Chung-Wei, Desilva, Heshani, Bhagavatheeswaran, Prabhu, Motzer, Robert J, Escudier, Bernard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639138/
https://www.ncbi.nlm.nih.gov/pubmed/36328377
http://dx.doi.org/10.1136/jitc-2022-005780

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639138/
https://www.ncbi.nlm.nih.gov/pubmed/36328377
http://dx.doi.org/10.1136/jitc-2022-005780

Ejemplares similares